FilingSEC EDGAR6-K
Radiopharm Theranostics to Present Positive RAD101 Phase 2b Interim Data at SNO26
· SEC accepted
StagePhase 2b
Filing content
Radiopharm Theranostics announced that positive interim data from its Phase 2b trial of RAD101 for brain metastases has been selected for presentation at the SNO26 annual meeting.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…